Skip to main content
$1.47 $0.02 (1.4%)

04:00 PM EST on 12/08/23

DermTech, Inc. (NASDAQ:DMTK)

CAPS Rating: 3 out of 5

Current Price $1.47 Mkt Cap $50.3M
Open $1.41 P/E Ratio -0.42
Prev. Close $1.47 Div. (Yield) $0.00 (0.0%)
Daily Range $1.38 - $1.50 Volume 5,135,601
52-Wk Range $1.12 - $6.43 Avg. Daily Vol. 294,741

Caps

How do you think NASDAQ:DMTK will perform against the market?

Add Stock to CAPS Watchlist

All Players

222 Outperform
6 Underperform
 

All-Star Players

9 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:DMTK Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Ransom65 (32.83)
Submitted April 18, 2022

DMTK has already gained FDA approval for its Melanoma sticker diagnostic technology they also own ALL patents on its tech. They are also in the process of completing phase 3 trials for the same sticker technology for the other two most common skin… More

hepanefc (78.02)
Submitted June 26, 2023

Bad profit ratios

NASDAQ:DMTK Summary

Fools bullish on NASDAQ:DMTK are also bullish on:

Fools bearish on NASDAQ:DMTK are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about DMTK.

Recs

1
Member Avatar hepanefc (78.02) Submitted: 6/25/2023 11:22:45 PM : Underperform Start Price: $2.15 NASDAQ:DMTK Score: +48.28

Bad profit ratios

Recs

1
Member Avatar Ransom65 (32.83) Submitted: 4/18/2022 5:42:38 PM : Outperform Start Price: $11.12 NASDAQ:DMTK Score: -91.61

DMTK has already gained FDA approval for its Melanoma sticker diagnostic technology they also own ALL patents on its tech. They are also in the process of completing phase 3 trials for the same sticker technology for the other two most common skin cancers Basal Cell and squeamish cell carcinomas with FDA approval for these they have the trifecta on ALL skin cancers for non invasive testing with 99.9% accuracy. DMTK has also made in roads with insurance companies Medicare as well as Anthem. Cost: The standard for diagnosing skin cancers are expensiveness and invasive biopsies the average cost to insurance companies is $2000 for this. DMTK's patch technology is 99.9% accurate and it's cost to insurance companies is under $800 thus saving insurers huge sums of money.As well as patients the pain and scaring of unnecessary biopsies. I see insurance companies not only coming on board with DMTK but making it a requirement for doctors to use the patch first biopsy second meaning if a doctor does a biopsy when the patch could have been used the billing will be rejected by the insurer. These are but a few of the ways DMTK will change the market over the next ten years. My wife and I hold a large position in DMTK and for us we see this is a 10X profit stock by 2030.

Recs

1
Member Avatar XMFTomFoolNC (87.50) Submitted: 10/13/2021 3:22:23 PM : Outperform Start Price: $31.57 NASDAQ:DMTK Score: -101.13

seems like a game changer, surprised sales not taking off faster then they are

Leaderboard

Find the members with the highest scoring picks in DMTK.

Score Leader

Jonnyboy5555

Jonnyboy5555 (89.80) Score: +132.71

The Score Leader is the player with the highest score across all their picks in DMTK.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
IndyAnthony 20.48 10/27/2021 Underperform 5Y $28.65 -94.76% +0.82% +95.59 0 Comment
wsmoot8796 77.55 2/24/2023 Underperform 1Y $3.80 -60.53% +16.38% +76.91 0 Comment
hepanefc 78.02 12/15/2022 Underperform 1Y $2.15 -30.23% +18.05% +48.28 1 Comment
Under5b < 20 12/23/2022 Underperform 5Y $1.79 -16.20% +21.22% +37.42 0 Comment
PAGEBOY54 86.43 9/20/2023 Underperform 3Y $1.64 -8.54% +3.65% +12.18 0 Comment
valari25 99.58 12/8/2023 Underperform 5Y $1.53 -1.96% +0.72% +2.68 0 Comment
Under5 56.90 11/3/2023 Outperform 5Y $1.50 0% +6.25% -6.25 0 Comment
muirmm 23.79 9/8/2023 Outperform 3Y $1.85 -18.92% +3.44% -22.36 0 Comment
TMFJoryko 79.30 11/4/2022 Outperform 5Y $1.72 -12.79% +23.83% -36.62 0 Comment
baf72167 < 20 12/6/2022 Outperform 5Y $2.44 -38.52% +15.22% -53.74 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DMTK.